by The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market is estimated to be valued at -2030 US$ 972.22 million in 2022 and is expected to exhibit a CAGR of 31.1% over the forecast period 2023, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed, progressive, life-threatening condition caused by the buildup of abnormal deposits of amyloid fibrils composed of misfolded transthyretin protein in the heart. ATTR-CM manifests with symptoms of heart failure including fatigue, shortness of breath, leg swelling, and loss of consciousness. Currently, there are limited treatment options available for patients with ATTR-CM.
Market Dynamics:
The increasing approvals of novel drugs to treat ATTR-CM is expected to drive the market growth over the forecast period. For instance, in 2019, the U.S. FDA approved Vyndaqel and Vyndamax developed by Pfizer Inc. for the treatment of ATTR-CM. Furthermore, the growing patient pool suffering from ATTR-CM is also anticipated to propel the market growth. As per studies, the prevalence of ATTR-CM in individuals aged 60-79 years is estimated to be around 40 people per million population. In addition, lack of awareness about ATTR-CM among physicians often leads to misdiagnosis or delayed diagnosis, which provides an opportunity for the key players to create more awareness among physicians to recognize signs and symptoms of ATTR-CM at an early stage and start prompt treatment.
SWOT Analysis
Strength: ATTR-CM treatment market possesses significant growth opportunities due to the rising prevalence of ATTR-CM worldwide. The treatment landscape is also expanding rapidly with the emergence of novel drugs. Support from regulatory bodies to fast-track pipeline products will further drive the market in the coming years.
Weakness: High costs associated with novel drug therapies for ATTR-CM remains a major challenge. Lack of awareness about ATTR-CM among both patients and physicians also hinders timely diagnosis and treatment seeking.
Opportunity: Increasing R&D investments by pharmaceutical players to develop advanced treatment options offers lucrative opportunities. Moreover, rising geriatric population susceptible to ATTR-CM augments market outlook.
Threats: Expiry of blockbuster drug patents may challenge the existing market landscape. Stringent regulations for approval of new drug therapies also poses a threat.
Key Takeaways
The Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Size is expected to witness high growth, exhibiting CAGR of 31.1% over the forecast period, due to increasing prevalence of ATTR-CM and robust product pipeline.
Market size: The global ATTR-CM treatment market was valued at US$ 748.80 million in 2020 and is anticipated to reach US$ 13,181.31 million by 2027 driven by approval and launch of novel therapies such as Onpattro, Vyndaqel and Inotersen.
Regional analysis: North America currently dominates the global market and is expected to maintain its lead over the forecast period owing to growing diagnosis rate and availability of advanced treatment options in the US. Europe is poised to exhibit substantial growth owing to increasing research collaborations.
Key players: Key players operating in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market are Pfizer Inc., GlaxoSmithKline Plc., Pfizer Inc., GlaxoSmithKline Plc., Eidos Therapeutics, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Prothena Corporation plc, Intellia Therapeutics, Inc., and Corino Therapeutics, Inc.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
